Acumen Pharmaceuticals (ABOS) Retained Earnings (2020 - 2026)
Acumen Pharmaceuticals (ABOS) posted Retained Earnings of -$467.2 million for Q1 2026, down 4.64% sequentially from -$446.5 million in Q4 2025, and down 32.01% YoY from -$687.2 million in Q1 2025.
Acumen Pharmaceuticals (ABOS) Retained Earnings (2020 - 2026) Analysis & Trends
Acumen Pharmaceuticals has reported Retained Earnings for 7 years, with the latest figure at -$467.2 million in Q1 2026.
- Quarterly Retained Earnings fell 32.01% year-over-year to -$467.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$467.2 million (down 32.01% YoY) and the FY2025 annual result came in at -$446.5 million, down 930108.33% from the prior year.
- Retained Earnings slipped to -$467.2 million in Q1 2026 per ABOS's latest filing, from -$446.5 million in the prior quarter.
- Over five years, Retained Earnings peaked at $354.3 million in Q2 2022 and troughed at -$467.2 million in Q1 2026.
- A 5-year average of -$161.2 million and a median of -$181.7 million in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings jumped 407.26% in 2022, then slumped 930108.33% in 2025.
- Over 5 years, Retained Earnings stood at -$751000.0 in 2022, then plunged by 29567.11% to -$222.8 million in 2023, then soared by 99.98% to -$48000.0 in 2024, then plunged by 930108.33% to -$446.5 million in 2025, then fell by 4.64% to -$467.2 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$467.2 million, -$446.5 million, and $109000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Acumen Pharmaceuticals | 226.87 Mn | 226.87 Mn | - | 557.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 557.19 Mn |
| Mar 31, 2026 | -467.20 Mn |
| Dec 31, 2025 | -446.50 Mn |
| Sep 30, 2025 | 109,000.00 |
| Jun 30, 2025 | -394.87 Mn |
| Mar 31, 2025 | -353.90 Mn |
| Dec 31, 2024 | -48,000.00 |
| Sep 30, 2024 | -288.00 Mn |
| Jun 30, 2024 | -164,000.00 |
| Mar 31, 2024 | -237.67 Mn |
| Dec 31, 2023 | -222.80 Mn |
| Sep 30, 2023 | -206.30 Mn |
| Jun 30, 2023 | -646,000.00 |
| Mar 31, 2023 | -181.70 Mn |
| Dec 31, 2022 | -751,000.00 |
| Sep 30, 2022 | -157.56 Mn |
| Jun 30, 2022 | 354.33 Mn |
| Mar 31, 2022 | -136.70 Mn |
| Dec 31, 2021 | -127.57 Mn |
| Sep 30, 2021 | -119.22 Mn |